Breast Cancer Screening Strategies for Women With <i>ATM, CHEK2</i>, and <i>PALB2</i> Pathogenic Variants

This analysis suggests that annual MRI screening starting at 30 to 35 years followed by annual MRI and mammography at 40 years may reduce breast cancer mortality by more than 50% for women with ATM, CHEK2, and PALB2 pathogenic variants. In the setting of MRI screening, mammography prior to 40 years may offer little additional benefit.